elite research semaglutide GLP-1 Receptor Agonist Reference Semaglutide Vs Tirzepatide | GLP

While Tirzepatide initially garnered attention for its effectiveness in managing blood sugar levels, it soon revealed its potential in another crucial aspect of health - weight management

In late 2023, the FDA also approved it for chronic weight management for people with obesity (body mass index of 30 kg/m 2 or higher) or overweight (body mass index of 27-29 kg/m 2 ) and at least one weight-related health condition, such as high blood pressure, Type 2 diabetes or high cholesterol

47 Because of the high prevalence of frailty and sarcopenic obesity in the HFpEF population, future studies are required to estimate the proportion of lean body mass loss versus fat loss on GLP-1 RA therapy to identify predictors of the disproportionate loss of muscle mass

The samples were processed by CytoFLEX (Beckman Coulter) and CytExpert 2.3 software